Current Opinion in Urology · Nov 3, 2026
The future of prostate cancer screening: from psa to smart risk-adapted pathways
By Adamcová V, Májek O, Hajcmanová K et al.
Purpose of review: Prostate cancer screening is undergoing a major transition from opportunistic prostate-specific antigen (PSA) testing to organized, risk-stratified screening programs. This review summarizes current evidence on established screening modalities, emerging biomarkers, and evolving screening pathways designed to improve the detection of clinically significant prostate cancer (csPCa) whilst reducing overdiagnosis and unnecessary interventions. Recent findings: Long-term follow-up from the European Randomized Study of Screening for Prostate Cancer confirms a reduction in prostate cancer-specific mortality associated with screening. Multiparametric magnetic resonance imaging (mpMRI) has become a central component of contemporary diagnostic pathways, improving the detection of csPCa and reducing unnecessary biopsies. Novel blood- and urine-based biomarkers, including PHI, 4Kscore, Stockholm3, SelectMDx, PCA3, MiPS, and ExoDx, have demonstrated improved risk stratification compared with PSA alone and may further refine biopsy selection. Organized screening programs increasingly integrate PSA, MRI, and biomarker-based assessment. Summary: Current evidence supports risk-adapted screening approaches combining PSA, mpMRI, and validated biomarkers to maximize the detection of clinically significant disease while minimizing screening-related harms. Future screening programs are likely to incorporate artificial intelligence and integrated risk-prediction models, enabling more personalized, accurate, and cost-effective prostate cancer early detection.
doi.org/10.1097/mou.0000000000001449PubMed 43023875Biomarkers